Effects of Combination Treatment with Losartan and Trandolapril on Office and Ambulatory Blood Pressures in Non-Diabetic Renal Disease: A COOPERATE-ABP Substudy-Reference-Cited by-同舟云学术

Effects of Combination Treatment with Losartan and Trandolapril on Office and Ambulatory Blood Pressures in Non-Diabetic Renal Disease: A COOPERATE-ABP Substudy

Published:2004 Issue:5 Volume:24 Page:543-548
ISSN:0250-8095
Container-title:American Journal of Nephrology
language:en
Short-container-title:Am J Nephrol

Author:

Nakao Naoyuki,Seno Hachiro,Kasuga Hirotake,Toriyama Takanobu,Kawahara Hirohisa,Fukagawa Masafumi

Publisher

S. Karger AG

Subject

Nephrology

Reference12 articles.

1. RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

2. Ambulatory blood pressure monitoring: an essential tool for blood pressure assessment in uraemic patients

3. Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy

4. Additive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type I Diabetic Patients with Diabetic Nephropathy

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease;Cochrane Database of Systematic Reviews;2023-07-19

2. Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors in Combination with Angiotensin-Receptor Blockers in Nondiabetic Chronic Kidney Disease: A Systematic Review and Meta-Analysis;Current Medicinal Chemistry;2021-12-08

3. Efficacy and safety of dual vs single renin–angiotensin–aldosterone system blockade in chronic kidney disease;Medicine;2021-09-03

4. Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitor in Combination with Angiotensin-Receptor Blocker in Chronic Kidney Disease Based on Dose: A Systematic Review and Meta-Analysis;Frontiers in Pharmacology;2021-05-06

5. Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial;Trials;2014-12